Scalper1 News
Generic and specialty drug giant Actavis beat Wall Street’s third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. Actavis’ (AGN) earnings, excluding one-time items, rose 53% over the year-earlier quarter to $3.19 a share, beating analysts’ consensus by 9 cents, according to Thomson Reuters. Revenue jumped 83% to $3.68 billion, topping consensus by about $40 Scalper1 News
Scalper1 News